The Nutlin-3a family of MDM2 antagonists displays anti-cancer activity by selectively inducing wtp53-dependent cell cycle arrest, apoptosis and in vivo tumor growth inhibition (Figure 1). This evidence concerns the gene MDM2 and neoplasm.